BONESUPPORT - Solid performance in Q4, critical juncture up ahead
2022-02-18 10:00:00
Redeye notes another record quarter for BONESUPPORT and is encouraged by the persistent sales growth during a most peculiar year for elective surgeries. We reiterate our Base Case of SEK 80 and argue that the stock could soon see a fairer price closer to its peers, with a potential FDA approval as a clear trigger.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/